search
Back to results

Implementation of STTR Strategies Among People Who Inject Drugs in Malaysia

Primary Purpose

HIV Seropositivity, Opioid-use Disorder

Status
Recruiting
Phase
Not Applicable
Locations
Malaysia
Study Type
Interventional
Intervention
Enhanced usual care (EUC)
Peer-based counseling
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Seropositivity

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • potential participants must meet the inclusion criteria for ART and MMT and begin receiving these treatments

Exclusion Criteria:

  • ART and MMT exclusion criteria include: liver enzymes greater than 5 times the upper limit of normal (ULN); liver failure (Childs Pugh Turcot Grade B or C).

Sites / Locations

  • Universiti Sains MalalysiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Enhanced usual care (EUC)

Fully Implemented Seek-Test-Treat-Retain (FI-STTR) model

Arm Description

The EUC consists of provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).

The FI-STTR care model will include the usual care supplemented by continuing education and coaching of medical staff at HIV/AIDS and MMT clinics and by provision of additional peer-based counseling intervention

Outcomes

Primary Outcome Measures

Virologic suppression
The rates of patients with virologic suppression (< 20 copies/mL) in the two care models will be assessed at 24 weeks

Secondary Outcome Measures

ART adherence, proportion of days when medication is taken as prescribed
ART adherence will be assessed by self-report using a timeline follow back (TLFB) methodology
Opioid use
Illicit opioid use measured by rates of opioid negative urine toxicology results and self-report
Depression scores
Center for Epidemiological Studies Depression Scale (CES-D) total score. The scale range is from 0 to 60; higher scores indicate more depression symptoms.
Psychiatric symptoms
Brief Symptom Inventory (BSI) a 53-item self-report inventory in which participants rate the extent to which they have been bothered (0 ="not at all" to 4="extremely") in the past week by various symptoms. The BSI has nine subscales designed to assess individual symptom groups: somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism. Higher scores indicate higher severity of symptoms.
Changes in the quality of life index
Short version of the World Health Organization Quality of Life (WHOQOL-BREF). The WHOQOL-BREF contains a total of 26 questions. In addition, two items from the Overall quality of Life and General Health facet are included. Four domains are assessed: Physical, Psychological, Social Relationship, and Environment.

Full Information

First Posted
June 11, 2019
Last Updated
October 4, 2023
Sponsor
Yale University
Collaborators
Universiti Sains Malaysia, National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT03987282
Brief Title
Implementation of STTR Strategies Among People Who Inject Drugs in Malaysia
Official Title
Implementation of Seek, Test, Treat & Retain Strategies Among People Who Inject Drugs in Malaysia
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 26, 2022 (Actual)
Primary Completion Date
March 1, 2025 (Anticipated)
Study Completion Date
August 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
Universiti Sains Malaysia, National Institute on Drug Abuse (NIDA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This pragmatic, multisite, implementation and effectiveness research evaluates a strategy to improve HIV treatment outcomes (increased rates of patients on ART with virological suppression, improved treatment retention and ART adherence) for people living with HIV (PLWH) with opioid use disorder (OUD). Engaging 4 large regional HIV/AIDS treatment centers in Malaysia, the study will evaluate barriers and facilitators for implementation of improved care model and will evaluate the comparative effectiveness of the model in a clinical trial. The research will provide critically important evidence for implementation of effective Seek-Test-Treat, and Retain models for PLWH and OUD throughout Malaysia and inform healthcare policy in other low to middle income countries and regions with limited healthcare resources.
Detailed Description
At each of the study locations, individuals testing HIV positive who also have OUD (n=4x70) will receive concurrent anti-retroviral therapy (ART) and methadone maintenance treatment (MMT) based on the usual care standards. Their patient level outcomes will be compared with individuals meeting the same inclusion criteria (n=4x70) and treated under the proposed improved model (post implementation evaluation). The usual care standard will consist of provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT). The improved care model will include the usual care supplemented by continuing education and coaching of medical staff at HIV/AIDS and MMT clinics and by provision of additional peer-based counseling intervention focused on behavioral skills and strategies that patients can learn and master to achieve uninterrupted, long-term ART treatment participation while continuing OUD recovery through MMT. The primary outcome measure, rates of patients with virologic suppression (< 20 copies/mL) in the two care models will be assessed at 24 weeks. The secondary outcomes, also followed for 24 weeks, will include ART adherence measured by objective measures (tenofovir dried blood spots, clinic records) and self-report; decreased illicit opioid use measured by rates of opioid negative urine toxicology results and self-report; and improvements on other health-related and functional status outcomes. Aim 1: To evaluate comparative effectiveness of fully implemented seek, test, treat and retain strategy (FI-STTR) the study will compare clinical, patient level, outcomes between enhanced usual care (EUC) and FI-STTR across the four study sites. Hypothesis: The investigators hypothesize a statistically significant effect on the primary outcome favoring the FI-STTR over EUC. It is also hypothesized that FI-STTR will be superior over EUC on all secondary outcomes. Concurrently at each study location, using implementation science mixed methods research tools and engaging key local stakeholders (treatment providers, patients, their families, and community activists), and evaluating clinical and healthcare data, the study will assess existing barriers (organizational, personnel, and community level factors) and uncover available resources and facilitators for a successful implementation of the improved care model. Aim 2: To assess existing barriers; organizational, personnel, community level factors; and available resources and potentially facilitating factors for successful implementation of the FI-STTR at HIV/AIDS clinics. There are no hypotheses specified a priori for Aim 2 of the proposed study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Seropositivity, Opioid-use Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Pre- versus post-implementation evaluation
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
560 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Enhanced usual care (EUC)
Arm Type
Active Comparator
Arm Description
The EUC consists of provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
Arm Title
Fully Implemented Seek-Test-Treat-Retain (FI-STTR) model
Arm Type
Experimental
Arm Description
The FI-STTR care model will include the usual care supplemented by continuing education and coaching of medical staff at HIV/AIDS and MMT clinics and by provision of additional peer-based counseling intervention
Intervention Type
Other
Intervention Name(s)
Enhanced usual care (EUC)
Intervention Description
Provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
Intervention Type
Behavioral
Intervention Name(s)
Peer-based counseling
Intervention Description
Peer-based counseling intervention focused on behavioral skills and strategies that patients can learn and master to achieve uninterrupted, long-term ART treatment participation while continuing OUD recovery through MMT
Primary Outcome Measure Information:
Title
Virologic suppression
Description
The rates of patients with virologic suppression (< 20 copies/mL) in the two care models will be assessed at 24 weeks
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
ART adherence, proportion of days when medication is taken as prescribed
Description
ART adherence will be assessed by self-report using a timeline follow back (TLFB) methodology
Time Frame
24 weeks
Title
Opioid use
Description
Illicit opioid use measured by rates of opioid negative urine toxicology results and self-report
Time Frame
24 weeks
Title
Depression scores
Description
Center for Epidemiological Studies Depression Scale (CES-D) total score. The scale range is from 0 to 60; higher scores indicate more depression symptoms.
Time Frame
24 weeks
Title
Psychiatric symptoms
Description
Brief Symptom Inventory (BSI) a 53-item self-report inventory in which participants rate the extent to which they have been bothered (0 ="not at all" to 4="extremely") in the past week by various symptoms. The BSI has nine subscales designed to assess individual symptom groups: somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism. Higher scores indicate higher severity of symptoms.
Time Frame
24 weeks
Title
Changes in the quality of life index
Description
Short version of the World Health Organization Quality of Life (WHOQOL-BREF). The WHOQOL-BREF contains a total of 26 questions. In addition, two items from the Overall quality of Life and General Health facet are included. Four domains are assessed: Physical, Psychological, Social Relationship, and Environment.
Time Frame
24 weeks

10. Eligibility

Sex
All
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: potential participants must meet the inclusion criteria for ART and MMT and begin receiving these treatments Exclusion Criteria: ART and MMT exclusion criteria include: liver enzymes greater than 5 times the upper limit of normal (ULN); liver failure (Childs Pugh Turcot Grade B or C).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marek C Chawarski, PhD
Phone
2039747602
Email
marek.chawarski@yale.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marek C Chawarski, PhD
Organizational Affiliation
Yale School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universiti Sains Malalysia
City
Gelugor
State/Province
Penang
ZIP/Postal Code
11800
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vicknasingam Kasinather, PhD
Phone
604 6532140
Email
vickna@usm.my

12. IPD Sharing Statement

Learn more about this trial

Implementation of STTR Strategies Among People Who Inject Drugs in Malaysia

We'll reach out to this number within 24 hrs